Akebia Therapeutics Reports First Quarter 2019 Financial Results; Announces Full Enrollment of Phase 3 INNO2VATE Studies and Announces Key Executive Appointments

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. GOOGL
5. APGE
6. MU
7. USO
8. HOOD
9. DFTX
10. RGNX

Go back to Akebia Therapeutics Reports First Quarter 2019 Financial Results; Announces Full Enrollment of Phase 3 INNO2VATE Studies and Announces Key Executive Appointments

Akebia Therapeutics (AKBA) Misses Q1 EPS by 22c, Revenues Miss

May 9, 2019 8:10 AM EDT

Akebia Therapeutics (NASDAQ: AKBA) reported Q1 EPS of ($0.62), $0.22 worse than the analyst estimate of ($0.40). Revenue for the quarter came in at $72.67 million versus the consensus estimate of $81.02 million.

Net Product Revenue for Auryxia Increases to $23.1 Million for Q1FY19, Up 12.1% from Q1FY18;Full Enrollment of Phase 3 INNO2VATE Studies; andAdditions to Executive Leadership Team to Support Commercial and Clinical... More